Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Leukemia, B-CellLymphoma, Non-Hodgkin'sAcute Lymphoblastic LeukemiaLeukemia, T-Cell
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma
- Conditions
- Granulocytic SarcomaRecurrent Adult Acute Myeloid Leukemia
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 49
- Registration Number
- NCT02484391
- Locations
- 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- DKMS gemeinnützige GmbH
- Target Recruit Count
- 281
- Registration Number
- NCT02461537
- Locations
- 🇩🇪
Robert-Bosch-Krankenhaus, Stuttgart, Baden-Wuerttemberg, Germany
🇩🇪Klinikum Nürnberg Nord, Nürnberg, Bavaria, Germany
🇩🇪Universitätsklinikum Münster, Münster, North Rhine-Westphalia, Germany
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Conditions
- Acute Lymphoid LeukemiaAcute Myeloid LeukemiaMixed Lineage Acute Leukemia
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02419755
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02400281
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
- Conditions
- Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 158
- Registration Number
- NCT02339740
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Naval Medical Center -San Diego, San Diego, California, United States
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 91
- Registration Number
- NCT02306291
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Alice Mims
- Target Recruit Count
- 23
- Registration Number
- NCT02299518
- Locations
- 🇺🇸
The State Ohio University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
- Conditions
- Childhood Acute Promyelocytic Leukemia
- Interventions
- Drug: ATODrug: RIFOther: intrathecal injection
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- South China Children's Leukemia Group
- Target Recruit Count
- 176
- Registration Number
- NCT02200978
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.